Abstract

AbstractBackgroundClinical trials are increasingly focused on pre‐manifest and early Alzheimer’s disease (AD). Accurately predicting those who transit from normal to MCI or from MCI to dementia/AD (true positives) versus non‐progressors (false positives) is challenging. Biomarker positivity and comorbidity information are often not sufficient to identify those who are destined to have symptom progressions. Accurate identification of progressors is important to avoid un‐necessary treatment as well as to improve trial efficiency.MethodUsing only clinical variables and big data analytics, we aimed to predict those who convert from normal to MCI and from MCI to AD, estimating probabilities of these conversions with a small set of selected clinical variables. This work updates our previous work using National Alzheimer’s Coordinating Center (NACC) Uniform Data Set Version 2. (1) We also generated a user‐friendly conversion probability calculator to estimate individual subject conversion. We used data from the NACC Uniform Data Set Version 3 and machine learning feature selection methods to identify clinical variables that predicted MCI and dementia conversion. We built a pipeline with machine learning techniques to test model performance.ResultUsing NACC data (frozen 3/2020), 577 subjects were used to predict conversions from normal to MCI within 4 years, and 538 and 882 subjects were used to predict conversion from MCI to AD within 2 years and 3 years, respectively. An exploratory analysis was also conducted for amnestic MCI (aMCI) conversion. For each prediction model, we selected 20 clinical variables optimizing predictions using Receiver Operating Characteristics Area‐under‐Curve (AUC). Our model achieved 82.1% prediction accuracy, 75.9% specificity, 85.1% sensitivity, and 80.5% AUC for MCI to AD conversion within 3 years. Similar results were obtained for normal to MCI conversion. The variables which ranked highest in predicting transitions include clinician’s judgement of subject’s meaningful cognitive impairment (conversion to MCI) and CDR community affairs item (conversion to AD in 3 years).ConclusionAlthough NACC UDS is extensive, our algorithm is based on a large sample size of potential trial participants who visited or are referred to Alzheimer’s Disease Centers. The probability calculator can be used to effectively pre‐screen and enrich trial participants.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.